ERBB2 and breast cancer: Another study revealed no correlation between CTC counts in HER2 tumors treated with targeted therapy and progression free and overall survivals (41), although this finding was not corroborated in other studies in which impacts on both survivals were observed for all breast cancer subtypes (35,42).